Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Recruiting · NCT06401824 · Registry updated 2025-05-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases | Neoplasms by Site, Thoracic Neoplasms, brain disorder, bronchial neoplasm, bronchogenic carcinoma, central nervous system cancer, central nervous system disorder, lung disorder, lung neoplasm, neoplasm, nervous system disorder, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2025-05-06 | NCT06401824 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Gilead Sciences | 180 |
| Maastricht University Medical Center | 157 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Maastricht University Medical Center | Maastricht | Netherlands | 23 |
| NKI-AVL | Amsterdam | Netherlands | 5 |
| University Medical Center Groningen | Groningen | Netherlands | 66 |